NMSA 1978 ch. 24, art. 2C — Harm Reduction | New Mexico Statutes Annotated 1978 (through the 2026 session) — New Mexico

NMSA 1978, § 24-2C-1 Short title

24-2C-1. Short title Sections 1 through 6 [24-2C-1 to 24-2C-6 NMSA 1978] of this act may be cited as the "Harm Reduction Act". Laws 1997, ch. 256, § 1.

NMSA 1978, § 24-2C-3 Definitions

24-2C-3. Definitions As used in the Harm Reduction Act: A. "department" means the department of health; and B. "participant" means a person who receives supplies or devices or services provided by the harm reduction program. Laws 1997, ch. 256, § 3; 2022, ch. 4, § 1.

NMSA 1978, § 24-2C-4 Harm reduction program created; department responsibilities

24-2C-4. Harm reduction program created; department responsibilities A. The department shall: (1) establish and administer a program that shall be known as the "harm reduction program" to reduce overdose mortality and other negative health outcomes associated with drug use; (2) pursuant to rules established by the department, qualify persons as harm reduction program participants, issue a document that identifies the bearer of the document as a participant and provide the bearer of the document with access to supplies, devices or services provided by the program; (3) compile data to assist in planning and evaluating efforts to combat overdose mortality and other negative health outcomes associated with drug use; and (4) make an annual report, including legislative recommendations, to the legislative health and human services committee by October 1 each year. B. The department shall appoint an advisory committee to include representation from: (1) the office of the attorney general; (2) the New Mexico state police division of the department of public safety; (3) the infectious disease prevention and control bureau of the department; (4) the director of the epidemiology and response division of the department or the director's designee; (5) a medical officer of the public health division of the department; and (6) other persons or representatives as chosen by the secretary of health to ensure a thorough and unbiased evaluation of the program established under the Harm Reduction Act. C. The advisory committee shall: (1) develop policies and procedures for evaluation of the harm reduction program; (2) develop criteria for data collection and program evaluation; and (3) meet as necessary to monitor and analyze data and produce a report on the harm reduction program's impact on overdose mortality and other negative health outcomes associated with drug use. D. The department may contract with private providers to operate the harm reduction program. E. The department shall promulgate rules as necessary for the administration of the Harm Reduction Act, including developing criteria for the types of supplies or devices provided pursuant to the harm reduction program and standards for distribution of those supplies or devices through that program. The criteria and standards shall be developed to provide supplies and devices in order to reduce: (1) cases of negative health outcomes associated with drug use, such as overdoses or the spread of infectious disease; and (2) harm by promoting reduced use of non-sterile items and improving participant engagement in harm reduction services and prevention education. Laws 1997, ch. 256, § 4; 2022, ch. 4, § 2.

NMSA 1978, § 24-2C-5 Program

24-2C-5. Program The harm reduction program shall provide participants with: A. sterile hypodermic syringes and needles in exchange for used hypodermic syringes, needles or other objects used to inject controlled substances or controlled substance analogs into the human body; B. other objects used to prepare or consume controlled substances or controlled substance analogs; C. supplies or devices used for testing controlled substances or controlled substance analogs for potentially dangerous adulterants; D. supplies or devices approved by the department for distribution in accordance with rules established pursuant to Subsection E of Section 24-2C-4 NMSA 1978; E. education on the prevention of: (1) the transmission of the human immunodeficiency virus and hepatitis B and C; and (2) drug overdose mortality and other negative health outcomes; and F. referral to substance abuse treatment services. Laws 1997, ch. 256, § 5; 2022, ch. 4, § 3.